Harshwardhan Singh

Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAFV600E inhibitors

H. Nandanwar, A. Emwas, A. Verma, 2022, RSC advances.

Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective

A. Emwas, A. Verma, Suresh Thareja, 2023, Pharmaceuticals.

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents

A. Emwas, A. Verma, Mariusz Jaremko, 2023, RSC advances.

Metal Complexes in Cancer Treatment: Journey So Far

A. Verma, Prateek Pathak, Pradeep Kumar, 2023, Chemistry & biodiversity.

Virtual screening, structure based pharmacophore mapping, and molecular simulation studies of pyrido[2,3-d]pyrimidines as selective thymidylate synthase inhibitors

A. Verma, Suresh Thareja, M. Grishina, 2023, Journal of biomolecular structure & dynamics.

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022

A. Emwas, A. Verma, Mariusz Jaremko, 2023, ACS omega.

In Silico Studies of Indole Derivatives as Antibacterial Agents

B. Narasimhan, Pradeep Kumar, Ankit Kumar Singh, 2023, Journal of pharmacopuncture.

MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives.

A. Emwas, Mariusz Jaremko, H. Khalilullah, 2023, RSC medicinal chemistry.

Design, one-pot synthesis, computational and biological evaluation of diaryl benzimidazole derivatives as MEK inhibitors.

Prateek Pathak, Pradeep Kumar, Ankit Kumar Singh, 2023, Journal of biomolecular structure & dynamics.